TREM2 R47H variant and risk for Alzheimer’s disease: assessment in a Greek population and updated meta-analysis

References

• 2016 Alzheimer’s disease facts and figures. Alzheimer Dement J Alzheimer Assoc. 2016;12(4):459–509.
   PubMedGoogle Scholar
• Aloizou AM, Siokas V, Vogiatzi C, et al. Pesticides, cognitive functions and dementia: a review. Toxicol Lett. 2020;326:31–51.
   PubMed Web of Science ®Google Scholar
• Aloizou AM, Pateraki G, Anargyros K, et al. Repetitive transcranial magnetic stimulation in the treatment of alzheimer’s disease and other dementias. Healthcare (Basel). 2021;9(8):949.
   PubMedGoogle Scholar
• Nousia A, Martzoukou M, Siokas V, et al. Beneficial effect of computer-based multidomain cognitive training in patients with mild cognitive impairment. Appl Neuropsychol Adult. 2021;28(6):717–726.
   PubMed Web of Science ®Google Scholar
• Lane CA, Hardy J, Schott JM. Alzheimer’s disease. Eur J Neurol. 2018;25(1):59–70.
   PubMed Web of Science ®Google Scholar
• Nousia A, Siokas V, Aretouli E, et al. Beneficial effect of multidomain cognitive training on the neuropsychological performance of patients with early-stage Alzheimer’s disease. Neural Plast. 2018;2018:2845176.
   PubMed Web of Science ®Google Scholar
• Mentis AF. Epigenomic engineering for Down syndrome. Neurosci Biobehav Rev. 2016;71:323–327.
   PubMed Web of Science ®Google Scholar
• Yamazaki Y, Zhao N, Caulfield TR, et al. Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. Nat Rev Neurol. 2019;15(9):501–518.
   PubMed Web of Science ®Google Scholar
• Dunn AR, O’Connell KMS, Kaczorowski CC. Gene-by-environment interactions in Alzheimer’s disease and Parkinson’s disease. Neurosci Biobehav Rev. 2019;103:73–80.
   PubMed Web of Science ®Google Scholar
• Eid A, Mhatre I, Richardson JR. Gene-environment interactions in alzheimer’s disease: a potential path to precision medicine. Pharmacol Ther. 2019;199:173–187.
   PubMed Web of Science ®Google Scholar
• Shi Y, Holtzman DM. Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight. Nat Rev Immunol. 2018;18(12):759–772.
   PubMed Web of Science ®Google Scholar
• Gratuze M, Leyns CE, Holtzman DM. New insights into the role of TREM2 in alzheimer’s disease. Mol Neurodegener. 2018;13(1):66.
   PubMed Web of Science ®Google Scholar
• Dardiotis E, Rikos D, Siokas V, et al. Assessment of TREM2 rs75932628 variant’s association with Parkinson’s disease in a Greek population and meta-analysis of current data. Int J Neurosci. 2021;131(6):544–548.
   PubMed Web of Science ®Google Scholar
• Yuan P, Condello C, Keene CD, et al. TREM2 haplodeficiency in mice and humans impairs the microglia barrier function leading to decreased amyloid compaction and severe axonal dystrophy. Neuron. 2016;90(4):724–739.
   PubMed Web of Science ®Google Scholar
• Lill CM, Rengmark A, Pihlstrom L, SLAGEN Consortium, et al. The role of TREM2 R47H as a risk factor for alzheimer’s disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson’s disease. Alzheimers Dement. 2015;11(12):1407–1416.
   PubMed Web of Science ®Google Scholar
• Korvatska O, Leverenz JB, Jayadev S, et al. R47H variant of TREM2 associated With Alzheimer disease in a large late-onset family: clinical, genetic, and neuropathological study. JAMA Neurol. 2015;72(8):920–927.
   PubMed Web of Science ®Google Scholar
• McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of alzheimer’s disease: report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on alzheimer’s disease. Neurology. 1984;34(7):939–944.
   PubMed Web of Science ®Google Scholar
• Stamati P, Siokas V, Aloizou AM, et al. Does SCFD1 rs10139154 polymorphism decrease alzheimer’s disease risk? J Mol Neurosci. 2019;69(2):343–350.
   PubMed Web of Science ®Google Scholar
• Dardiotis E, Panayiotou E, Siokas V, et al. Gene variants of adhesion molecules predispose to MS: a case-control study. Neurol Genet. 2019;5(1):e304.
   PubMed Web of Science ®Google Scholar
• Siokas V, Kardaras D, Aloizou AM, et al. BDNF rs6265 (Val66Met) polymorphism as a risk factor for blepharospasm. Neuromolecular Med. 2019;21(1):68–74.
   PubMed Web of Science ®Google Scholar
• Siokas V, Kardaras D, Aloizou AM, et al. Lack of association of the rs11655081 ARSG gene with blepharospasm. J Mol Neurosci. 2019;67(3):472–476.
   PubMed Web of Science ®Google Scholar
• Lu Y, Liu W, Wang X. TREM2 variants and risk of alzheimer’s disease: a meta-analysis. Neurol Sci. 2015;36(10):1881–1888.
   PubMed Web of Science ®Google Scholar
• Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J National Cancer Inst. 1959;22(4):719–748.
   PubMed Web of Science ®Google Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trial. 1986;7(3):177–188.
   PubMedGoogle Scholar
• Furuya-Kanamori L, Barendregt JJ, Doi SAR. A new improved graphical and quantitative method for detecting bias in meta-analysis. Int J Evid Based Healthc. 2018;16(4):195–203.
   PubMed Web of Science ®Google Scholar
• Sohani ZN, Meyre D, de Souza RJ, et al. Assessing the quality of published genetic association studies in meta-analyses: the quality of genetic studies (Q-Genie) tool. BMC Genet. 2015;16:50.
   PubMed Web of Science ®Google Scholar
• Siokas V, Aslanidou P, Aloizou AM, et al. Does the CD33 rs3865444 polymorphism confer susceptibility to alzheimer’s disease? J Mol Neurosci. 2020;70(6):851–860.
   PubMed Web of Science ®Google Scholar
• Arboleda-Bustos CE, Ortega-Rojas J, Mahecha MF, et al. The p.R47H variant of TREM2 gene is associated With late-onset Alzheimer disease in Colombian population. Alzheimer Dis Assoc Disord. 2018;32(4):305–308.
   PubMed Web of Science ®Google Scholar
• Benitez BA, Cooper B, Pastor P, et al. TREM2 is associated with the risk of alzheimer’s disease in Spanish population. Neurobiol Aging. 2013;34(6):1711.e15-7–1711.e17.
   PubMed Web of Science ®Google Scholar
• Bertram L, Parrado AR, Tanzi RE. TREM2 and neurodegenerative disease. N Engl J Med. 2013;369(16):1565.
   PubMed Web of Science ®Google Scholar
• Cuyvers E, Bettens K, Philtjens S, BELNEU Consortium, et al. Investigating the role of rare heterozygous TREM2 variants in alzheimer’s disease and frontotemporal dementia. Neurobiol Aging. 2014;35(3):726.e11-9–726.e19.
   PubMed Web of Science ®Google Scholar
• Dalmasso MC, Brusco LI, Olivar N, et al. Transethnic meta-analysis of rare coding variants in PLCG2, ABI3, and TREM2 supports their general contribution to alzheimer’s disease. Transl Psych. 2019;9(1):55.
   PubMed Web of Science ®Google Scholar
• Finelli D, Rollinson S, Harris J, et al. TREM2 analysis and increased risk of alzheimer’s disease. Neurobiol Aging. 2015;36(1):546.e9-13–546.13.
   PubMed Web of Science ®Google Scholar
• Giraldo M, Lopera F, Siniard AL, et al. Variants in triggering receptor expressed on myeloid cells 2 are associated with both behavioral variant frontotemporal lobar degeneration and alzheimer’s disease. Neurobiol Aging. 2013;34(8):2077.e11-8–2077.e18.
   PubMed Web of Science ®Google Scholar
• Gonzalez Murcia JD, Schmutz C, Munger C, et al. Assessment of TREM2 rs75932628 association with alzheimer’s disease in a population-based sample: the cache county study. Neurobiol Aging. 2013;34(12):2889.e11-3–2889.e13.
   PubMed Web of Science ®Google Scholar
• Guerreiro R, Wojtas A, Bras J, Alzheimer Genetic Analysis Group, et al. TREM2 variants in alzheimer’s disease. N Engl J Med. 2013;368(2):117–127.
   PubMed Web of Science ®Google Scholar
• Hooli BV, Parrado AR, Mullin K, et al. The rare TREM2 R47H variant exerts only a modest effect on Alzheimer disease risk. Neurology. 2014;83(15):1353–1358.
   PubMed Web of Science ®Google Scholar
• Jiao B, Liu X, Tang B, et al. Investigation of TREM2, PLD3, and UNC5C variants in patients with alzheimer’s disease from mainland China. Neurobiol Aging. 2014;35(10):2422.e9–e11.
   PubMed Web of Science ®Google Scholar
• Jin SC, Benitez BA, Karch CM, et al. Coding variants in TREM2 increase risk for alzheimer’s disease. Hum Mol Genet. 2014;23(21):5838–5846.
   PubMed Web of Science ®Google Scholar
• Jin SC, Carrasquillo MM, Benitez BA, et al. TREM2 is associated with increased risk for alzheimer’s disease in African Americans. Mol Neurodegener. 2015;10:19.
   PubMed Web of Science ®Google Scholar
• Jonsson T, Stefansson H, Steinberg S, et al. Variant of TREM2 associated with the risk of alzheimer’s disease. N Engl J Med. 2013;368(2):107–116.
   PubMed Web of Science ®Google Scholar
• Landoulsi Z, Ben Djebara M, Kacem I, et al. Genetic analysis of TREM2 variants in Tunisian patients with alzheimer’s disease. Med Princ Pract. 2018;27(4):317–322.
   PubMed Web of Science ®Google Scholar
• Ma J, Zhou Y, Xu J, et al. Association study of TREM2 polymorphism rs75932628 with late-onset Alzheimer’s disease in Chinese Han population. Neurol Res. 2014;36(10):894–896.
   PubMed Web of Science ®Google Scholar
• Mehrjoo Z, Najmabadi A, Abedini SS, et al. Association study of the TREM2 gene and identification of a novel variant in exon 2 in Iranian patients with late-onset Alzheimer’s disease. Med Princ Pract. 2015;24(4):351–354.
   PubMed Web of Science ®Google Scholar
• Miyashita A, Wen Y, Kitamura N, et al. Lack of genetic association between TREM2 and late-onset alzheimer’s disease in a Japanese population. J Alzheimers Dis. 2014;41(4):1031–1038.
   PubMed Web of Science ®Google Scholar
• Pottier C, Wallon D, Rousseau S, et al. TREM2 R47H variant as a risk factor for early-onset alzheimer’s disease. J Alzheimers Dis. 2013;35(1):45–49.
   PubMed Web of Science ®Google Scholar
• Rosenthal SL, Bamne MN, Wang X, et al. More evidence for association of a rare TREM2 mutation (R47H) with alzheimer’s disease risk. Neurobiol Aging. 2015;36(8):2443.e21-6–2443.e26.
   PubMed Web of Science ®Google Scholar
• Roussos P, Katsel P, Fam P, et al. The triggering receptor expressed on myeloid cells 2 (TREM2) is associated with enhanced inflammation, neuropathological lesions and increased risk for alzheimer’s dementia. Alzheimers Dement. 2015;11(10):1163–1170.
   PubMed Web of Science ®Google Scholar
• Ruiz A, Dols-Icardo O, Bullido MJ, Dementia Genetic Spanish Consortium (DEGESCO), et al. Assessing the role of the TREM2 p.R47H variant as a risk factor for alzheimer’s disease and frontotemporal dementia. Neurobiol Aging. 2014;35(2):444.e1-4–444.e4.
   PubMed Web of Science ®Google Scholar
• Slattery CF, Beck JA, Harper L, et al. R47H TREM2 variant increases risk of typical early-onset alzheimer’s disease but not of prion or frontotemporal dementia. Alzheimers Dement. 2014;10(6):602–608.e4.
   PubMed Web of Science ®Google Scholar
• Wang P, Guo Q, Zhou Y, et al. Lack of association between triggering receptor expressed on myeloid cells 2 polymorphism rs75932628 and late-onset alzheimer’s disease in a Chinese Han population. Ann Human Genetic. 2018;28(1):16–18.
   Google Scholar
• Yu JT, Jiang T, Wang YL, et al. Triggering receptor expressed on myeloid cells 2 variant is rare in late-onset alzheimer’s disease in Han Chinese individuals. Neurobiol Aging. 2014;35(4):937.e1-3–937.e3.
   PubMed Web of Science ®Google Scholar
• Rikos D, Siokas V, Aloizou AM, et al. TREM2 R47H (rs75932628) variant is unlikely to contribute to multiple sclerosis susceptibility and severity in a large Greek MS cohort. Mult Scler Relat Disord. 2019;35:116–118.
   PubMed Web of Science ®Google Scholar
• Lobach I. Bias in parameter estimates due to omitting gene-environment interaction terms in case-control studies. Genet Epidemiol. 2018;42(8):838–845.
   PubMed Web of Science ®Google Scholar
• Singh NK, Chhillar N, Banerjee BD, et al. Gene-environment interaction in alzheimer’s disease. Am J Alzheimers Dis Other Demen. 2012;27(7):496–503.
   PubMed Web of Science ®Google Scholar
• Styczyńska M, Strosznajder JB, Religa D, et al. Association between genetic and environmental factors and the risk of alzheimer’s disease. Folia Neuropathol. 2008;46(4):249–254.
   PubMed Web of Science ®Google Scholar
• Van Duijn CM, Clayton DG, Chandra V, EURODEM Risk Factors Research Group, et al. Interaction between genetic and environmental risk factors for alzheimer’s disease: a reanalysis of case-control studies. Genet Epidemiol. 1994;11(6):539–551.
   PubMed Web of Science ®Google Scholar
• Takatori S, Wang W, Iguchi A, et al. Genetic risk factors for Alzheimer disease: emerging roles of microglia in disease pathomechanisms. Adv Exp Med Biol. 2019;1118:83–116.
   PubMed Web of Science ®Google Scholar
• Yin Z, Raj D, Saiepour N, et al. Immune hyperreactivity of Aβ plaque-associated microglia in alzheimer’s disease. Neurobiol Aging. 2017;55:115–122.
   PubMed Web of Science ®Google Scholar
• Wang Y, Ulland TK, Ulrich JD, et al. TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques. J Exp Med. 2016;213(5):667–675.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Wu X, Li X, et al. TREM2 Is a receptor for β-Amyloid that mediates microglial function. Neuron. 2018;97(5):1023–1031.e7.
   PubMed Web of Science ®Google Scholar
• Jay TR, Miller CM, Cheng PJ, et al. TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in alzheimer’s disease mouse models. J Exp Med. 2015;212(3):287–295.
   PubMed Web of Science ®Google Scholar
• Jay TR, Hirsch AM, Broihier ML, et al. Disease progression-dependent effects of TREM2 deficiency in a mouse model of alzheimer’s disease. J Neurosci. 2017;37(3):637–647.
   PubMed Web of Science ®Google Scholar
• Dardiotis E, Siokas V, Moza S, et al. Pesticide exposure and cognitive function: results from the hellenic longitudinal investigation of aging and diet (HELIAD). Environ Res. 2019;177:108632.
   PubMed Web of Science ®Google Scholar
• Ruszkiewicz JA, Tinkov AA, Skalny AV, et al. Brain diseases in changing climate. Environ Res. 2019;177:108637.
   PubMed Web of Science ®Google Scholar
• Dardiotis E, Siokas V, Sokratous M, et al. Genetic polymorphisms in amyotrophic lateral sclerosis: evidence for implication in detoxification pathways of environmental toxicants. Environ Int. 2018;116:122–135.
   PubMed Web of Science ®Google Scholar
• Mentis AA, Pantelidi K, Dardiotis E, et al. Precision medicine and global health: the good, the bad, and the ugly. Front Med (Lausanne). 2018;5:67.
   PubMed Web of Science ®Google Scholar